Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Open Orphan Plc ( (GB:HVO) ) has shared an announcement.
hVIVO plc announced the exercise of 202,092 options by employees, including the Chief Financial Officer, Stephen Pinkerton, under the company’s 2020 Long Term Incentive Plan. This transaction will result in the issuance of new ordinary shares, increasing the total number of shares in issue to 687,014,088, with equal voting rights. This development reflects the company’s ongoing commitment to incentivizing its employees and could impact its market positioning by potentially increasing shareholder value.
More about Open Orphan Plc
hVIVO plc is a full-service Contract Research Organisation (CRO) and a global leader in human challenge trials. The company provides comprehensive clinical development services to a diverse client base, including major biopharma companies. It specializes in human challenge trials for infectious and respiratory diseases, utilizing its state-of-the-art quarantine facility in London. hVIVO also offers virology and immunology laboratory services under the hLAB brand and operates clinical trial services in Germany through its subsidiary CRS. Another subsidiary, Venn Life Sciences, provides consulting and biometry services to the biopharma sector.
YTD Price Performance: -27.80%
Average Trading Volume: 3,219,357
Technical Sentiment Signal: Strong Buy
Current Market Cap: £98.21M
See more data about HVO stock on TipRanks’ Stock Analysis page.